NCT00096941

A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

An Open-Label, Multicenter Extension Study of Pertuzumab (rhuMAb 2C4) in Subjects Treated With Pertuzumab in a Previous Genentech-Sponsored Phase II Cancer Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open label extension study. Subjects who have completed treatment in the parent study of pertuzumab, either alone or with a combination agent, and who received at least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if they are continuing to receive clinical benefit.

Conditions

• Solid Cancers

Interventions

Type	Name	Description
DRUG	Pertuzumab	Pertuzumab was supplied as a single-use liquid formulation.

Timeline

• Start date: 2005-05-01
• Primary completion: 2007-10-01
• Completion: 2007-10-01
• First posted: 2004-11-18
• Last updated: 2015-06-11
• Results posted: 2015-06-11